Hormones and Agents Affecting Hormonal Mechanism: Calcium Regulating Agents
OREOS12 “Reosteo FC table” 35 mg/tab
適應症：一、治療及預防停經後的骨質疏鬆症。二、治療具有高度骨折風險(定義為有骨質疏鬆症骨折病史，或具有多項骨折危險因子)之骨質疏鬆症男性患者，以增加骨質(Bone Mass)。
Usual dose:
Osteoporosis, male: 35 mg ORALLY once weekly; take with 6 to 8 ounces of water at least 30 minutes prior to the first food or drink of the day; if dietary intake is inadequate, patients should also receive supplemental calcium and vitamin D.
Postmenopausal osteoporosis: 35 mg ORALLY once weekly, or one 75-mg tablet ORALLY on 2 consecutive days for a total of 2 tablets each month, or one 150-mg tablet ORALLY once a month; take with 6 to 8 ounces of water at least 30 minutes prior to the first food or drink of the day; if dietary intake is inadequate, patients should also receive supplemental calcium and vitamin D.
Contraindication:
Esophageal abnormalities (eg, stricture or achalasia) that delay esophageal emptying.
Hypersensitivity to risedronate or any component of the product.
Hypocalcemia.
Inability to sit or stand upright for at least 30 minutes.
Adverse effect:
Common: rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease, influenza-like illness.
Serious: cardiac dysrhythmia, peripheral edema, arthralgia, aseptic necrosis of bone of jaw, bone pain, myalgia, iritis, uveitis, nephrolithiasis, benign prostatic hyperplasia.